DDInter629 DDInter1658
Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher disease, the accumulation of glucosylceramide leads to the formation of Gaucher cells that infiltrate the liver, spleen, bone marrow and other organs. This leads to complications such as anemia and thrombocytopenia.[L41404,A246384] By inhibiting glucosylceramide synthase, eliglustat reduces the accumulation of glucosylceramide. Eliglustat is mainly metabolized by CYP2D6. Patients selected for eliglustat treatment undergo an FDA-cleared genotyping test to establish if they are CYP2D6 extensive metabolizers (
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Eliglustat {u} may cause a minor interaction that can limit clinical effects when taken with {v} Donepezil
Eliglustat {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Eliglustat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fenfluramine
Eliglustat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naldemedine
Eliglustat {u} may lead to a major life threatening interaction when taken with {v} Bepridil
Eliglustat {u} may lead to a major life threatening interaction when taken with {v} Dacomitinib
Eliglustat may cause a minor interaction that can limit clinical effects when taken with Donepezil
Eliglustat may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine
Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Eliglustat may lead to a major life threatening interaction when taken with Bepridil
Eliglustat may lead to a major life threatening interaction when taken with Dacomitinib